Covington plant will add 3 million liters of plasma fractionation capacity annually.

Baxter confirmed plans to invest over $1 billion during the next five years in the construction of a manufacturing facility in Georgia to support the growth of its plasma-based treatments for immune disorders, trauma and other critical conditions. Work at the Covington site will start later this year and include the construction of facilities supporting plasma fractionation, purification and fill-finish, and a testing lab. The Covington site will also have the flexibility and infrastructure needed to expand further in the future.

The new facility is expected to start commercial production 2018, with the plasma fractionation plant providing additional capacity of up to 3 million liters annually when fully operational. ”This investment demonstrates our long-term commitment to patients around the world who rely on our plasma-based therapies,” said Robert L. Parkinson, Jr., Baxter’s chairman and CEO.

In parallel with building its new plant, Baxter says it also expects to create more than 200 jobs at its site in Illinois, including positions associated with expanding fill-finish capacity at its existing manufacturing facility in Round Lake. Overall the firm expects to create more than 1,500 full-time positions in Georgia and over another 2,000 in total across multiple U.S. locations.

Previous articleAcorda Eyes Additions to Neurodegenerative Disease Drug Pipeline
Next articleMJFF Sponsors Phase Ib Trial with Sanofi’s Parkinson Disease Candidate